Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07419880 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Name: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer — clinical trial record (NCT07419880)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RECLAIM

StatusNot Yet Recruiting

PhasePhase 2

SponsorFudan University

Started2027-01-01

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 11 months later Jan 30, 2027 → Dec 31, 2027

See other at-risk trials from Fudan University

Amendment history

2026-09-26

Primary completion pushed: 2027-01-30 → 2027-12-31

Completion pushed: 2027-04-30 → 2028-06-30

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Triple-Negative Breast Cancer

594 trials monitored

See 37 trials at risk

RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer

Trial Details

NCT Number	NCT07419880
Lead Sponsor	Fudan University
Conditions	Triple -Negative Breast Cancer
Enrollment	46 participants
Start Date	2027-01-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-25